[go: up one dir, main page]

AU2003242265A1 - Combined effects of therapeutic or preventive agent composition for bone breakage - Google Patents

Combined effects of therapeutic or preventive agent composition for bone breakage

Info

Publication number
AU2003242265A1
AU2003242265A1 AU2003242265A AU2003242265A AU2003242265A1 AU 2003242265 A1 AU2003242265 A1 AU 2003242265A1 AU 2003242265 A AU2003242265 A AU 2003242265A AU 2003242265 A AU2003242265 A AU 2003242265A AU 2003242265 A1 AU2003242265 A1 AU 2003242265A1
Authority
AU
Australia
Prior art keywords
therapeutic
agent composition
preventive agent
combined effects
bone breakage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003242265A
Inventor
Yukie Ogawa
Masahiko Ohtsuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of AU2003242265A1 publication Critical patent/AU2003242265A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2003242265A 2002-06-07 2003-06-06 Combined effects of therapeutic or preventive agent composition for bone breakage Abandoned AU2003242265A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002166745 2002-06-07
JP2002-166745 2002-06-07
PCT/JP2003/007221 WO2003103710A1 (en) 2002-06-07 2003-06-06 Combined effects of therapeutic or preventive agent composition for bone breakage

Publications (1)

Publication Number Publication Date
AU2003242265A1 true AU2003242265A1 (en) 2003-12-22

Family

ID=29727638

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003242265A Abandoned AU2003242265A1 (en) 2002-06-07 2003-06-06 Combined effects of therapeutic or preventive agent composition for bone breakage

Country Status (3)

Country Link
AU (1) AU2003242265A1 (en)
TW (1) TW200400830A (en)
WO (1) WO2003103710A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2492871C2 (en) * 2008-08-01 2013-09-20 АКСИС, Инс. Therapeutic or preventive drug for treating osteoarthritis
KR101684246B1 (en) 2010-01-29 2016-12-08 가부시키가이샤 아크시스 Injection containg treatment agent for osteoarthritis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE412746T1 (en) * 1998-05-14 2008-11-15 Immunex Corp METHOD FOR INHIBITING THE EFFECT OF OSTEOCLASTS
PL347559A1 (en) * 1998-10-28 2002-04-08 Snow Brand Milk Products Co Ltd Remedies for bone metabolic errors
AU761544C (en) * 1999-05-24 2004-02-12 Sankyo Company Limited Medicinal compositions containing anti-Fas antibody
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
PE20030340A1 (en) * 2001-08-28 2003-04-05 Sankyo Co METHOD FOR THE TREATMENT OR PREVENTION OF BONE WEAR

Also Published As

Publication number Publication date
WO2003103710A1 (en) 2003-12-18
TW200400830A (en) 2004-01-16

Similar Documents

Publication Publication Date Title
IL160713A0 (en) Compositions containing oxyntomodulin for prevention or treatment of excess weight
AU2003205226A1 (en) Compositions for treatment or prevention of bioterrorism
HUP0402075A3 (en) Compositions for treatment of common cold
AU2001233081A1 (en) Composition for treatment of stress
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
AU2002323823A1 (en) Medicament for prevention and treatment of fracture and osteoporosis
HUP0002509A3 (en) Combination composition for treatment of migraine
AU2003211610A1 (en) Pharmaceutical compositions for the treatment or prevention of osteoporosis
AU2003237969A1 (en) Pharmaceutical composition comprising calcium channel blockers for the treatment of pain
HUP0500199A3 (en) Pharmaceutical composition comprising arsenite for the treatment of malignancy
AU2003242265A1 (en) Combined effects of therapeutic or preventive agent composition for bone breakage
AU2003270202A8 (en) Pharmaceutical compositions useful for the treatment of cancers
AU2003266960A1 (en) Composition for the treatment of pain, especially for the treatment of articular pain
AU2003285883A1 (en) Methods and compositions for determining risk of treatment toxicity
AU2003240174A1 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
AU2003272327A1 (en) Methods of bone healing
AU2003252185A8 (en) Topical composition for the treatment of scar tissue
EP1557169A4 (en) Therapeutic and/or preventive agent for dyschezia
AU2001232734A1 (en) Compositions containing potential spla2 inhibitors for the treatment of pain
AU2003266621A1 (en) Medicinal composition for treatment for or prevention of visceral pain
AU2002308878A1 (en) Compositions for promoting healing of bone fracture
AU2003273569A1 (en) Calcium-containing composition from bone tissue
AU2003229335A8 (en) Compositions and methods for treatment of wounds
IL151799A0 (en) Composition for treatment of onychomycosis

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase